Work

Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study

Year: 2016

Type: conference-abstract

Source: European Respiratory Journal

DOI: 10.1183/13993003.congress-2016.pa990

Authors: Robert Fogel, Kenneth R. Chapman, Claus F. Vogelmeier, Angel FowlerTaylor, Tim Ayers, Chau Thach, Sarah Whelan, Karyn Clerkin, Francesco Patalano, Donald Banerji

Institutions: Novartis (Switzerland), Novartis (United States), University Health Network, Toronto Western Hospital, Universitätsklinikum Gießen und Marburg, Novartis (Ireland)

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2555599806

Cites:

Cited by:

Related to: 10